spacer
home > epc > spring 2002 > global parallel trade - a growing concern
PUBLICATIONS
European Pharmaceutical Contractor

Global Parallel Trade - A Growing Concern

In an industry traditionally confined to Europe, evidence suggests that parallel trade is now expanding globally. This relatively young, yet highly controversial industry sector is breaking free from the confines of the EU and is taking a foothold in non-EU countries such as Russia, South Africa, India, and the Philippines, according to a new report published by Reuters Business Insight. Within the EU, parallel trade is also shown to be expanding as a result of increased numbers of parallel import licences granted, EU enlargement, national cost-containment drives on drug spending, and litigation victories for parallel traders - activities that are forecast to drive the parallel trade market to a US$7.4 billion industry by 2006. In The Global Parallel Trade Outlook, 2001-2006, new trends in parallel trade are identified along with potential new market opportunities that the industry has created under the current political, legal and regulatory framework of 27 countries. The report's author provides a short commentary on how parallel trade is expanding and what this could mean for the global pharmaceutical industry.

In the EU, parallel trade or parallel distribution has been a legitimate industry since the 1970s, when drugs were bought from low-priced countries and sold in high-priced countries despite the availability and distribution of locally manufactured equivalents in the import and export countries. There are a number of advantages and disadvantages to parallel trade. The most obvious and important is the financial reward from selling cheaply purchased drugs to higher priced economies. In addition, parallel trade stimulates competition and benefits the health care provider and patient through lower drug prices. The downside, however, includes the loss of revenue for the manufacturer, erosion of domestic sales, and not least is the point that parallel trade is a highly litigious practice costing firms millions of dollars each year.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Tim Atkinson, Independent Biopharmaceutical Analyst

Tim Atkinson BSc (Hons), a former Biomedical Scientist and Medical Editor and Writer, has worked for over 10 years in scientific and medical publishing environments. He has written on a number of industry-related topics ranging from pharmaceutical e-commerce to drug delivery and biomaterials. He is currently working as an independent Biopharmaceutical Analyst on assignments for companies such as Reuters Business Insight and IMS Health where he has produced in-depth market intelligence business and health care reports aimed at senior executives in the pharmaceutical industry. With over 15 publications to date, Tim is currently researching and writing on lifestyle drugs and innovation in R&D.

spacer
Tim Atkinson
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Destiny Pharma appoints MedPharm to develop new XF-platform drug formulations

Destiny Pharma, a clinical stage biotechnology company focused on the development of novel antimicrobial drugs, is pleased to announce that it has appointed MedPharm as its expert partner to develop new topical formulations of the Company’s novel XF-platform compounds. These new treatments for dermal and ocular infections are part of its second clinical programme to address the global problem of anti-microbial resistance (AMR). MedPharm is a world leading contract provider of topical and transdermal product design and formulation development services using sophisticated in vitro models to de-risk development programmes.
More info >>

White Papers

Stripping the confusion out of PVC curtains... and a new seat range.

Teknomek Ltd

With the ever-growing trend towards modularisation of clean rooms and laboratories; Teknomek have responded with a new range of PVC strip curtains, suitable for use in environments where maintaining clean airflow is critical. This new PVC curtain range includes specialist perforated and electrostatic discharge alternatives to the standard options of clear and polar (-25oC) versions.
More info >>

 
Industry Events

CPhI & P-MEC India

26-28 November 2019, India Expo Centre, Greater Noida, Delhi NCR, India

As the pharma industry looks increasingly towards India for high quality, low cost pharma solutions, CPhI & P-MEC India is the ideal event for companies wanting to pick up on the latest trends and innovations the market has to offer. At CPhI & P-MEC India, you will meet the movers and shakers from India's pharma machinery, technology and ingredients industries, giving you a competitive advantage that will help grow your business.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement